We develop proprietary drug delivery technologies and drug formulas in the field of oncology, dermatology and autoimmune diseases

News

26 June 2020

Biotts: an innovative form of anti-diabetic drug being developed in Wrocław

We are just witnessing an innovative form of anti-diabetic drug being developed in Wrocław. Polish researchers have received more than 11 million ...

Read

15 June 2020

Parkiet: Polish biotechnology is getting ready to jump

Parkiet: In the first months of 2020, the number of transactions carried out by PE and VC funds decreased. One of the few actual investments was ...

Read

05 June 2020

HCC Online: Start-ups in medicine

Stay tuned. On June 8, our CEO, Paweł Biernat will discuss our unique transdermal carrier and other topics as part of the Health Challenges ...

Read

22 May 2020

Biotts has acquired 7 mln PLN from investors

We are happy to announce that the Montis Capital fund has invested over 7 mln PLN in the  Biotts SA. Biotts – a Wroclaw-based startup ...

Read
 

About BIOTTS

BIOTTS S.A. is a Polish biotechnological company that develops proprietary drug delivery technologies and drug formulas in the field of oncology, dermatology, and autoimmune diseases. The team of Biotts technologists has developed a proprietary technology for obtaining a universal transdermal therapeutic system: MTC-Y. Thanks to the unique properties of the system, it is possible to increase the bioavailability of active substances by several times, allowing active substances to penetrate through skin barriers up to several centimetres, reaching soft tissues and bones. The unique transdermal MTC-Y system can be easily modified to achieve a targeted action in pathologically changed tissues. By increasing the bioavailability of the substance, it is possible to reduce the therapeutic dose, while maintaining the original effect and, at the same time, reducing the side effects. The unique transdermal Biotts system enables the transport of one to several active substances, thanks to which it is possible to design multi-component drugs. Through simple modifications of the system, it is also possible to design medicines with a modified release profile for the medicinal substance.

How it works transdermal Biotts technology:

With more than thirty years of experience, the Research and Development Team is able to effectively create proprietary medicines, solve complex technological problems and create unique solutions to help people all over the world.

BIOTTS S.A. also provides research and development services for pharmaceutical, biotechnological, cosmetic and chemical companies from all over the world.

We have provided the market with a wide variety of solutions, including: a non-aggregating nanocarrier used in the production of vitamin preparations, anti-allergic drugs, semi-solid forms of a drug with a deep penetration carrier, semi-solid forms of a drug accelerating tissue reconstruction, cosmetic products with increased bioavailability based on natural resources, medicinal gels, stabilised and naturally preserved omega acids, and functional food formulas.

BIOTTS S.A.
Duńska 7 st.
54-427 Wrocław
office@biotts.com

Laboratories
Wrocław Technology Park
Omega Building
Duńska 7 street
54-424 Wrocław